Puberty Suppression and Cardiometabolic Health
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age9-14
SponsorUniversity of Colorado, Denver
About this trial
This observational study will evaluate the effect of puberty suppression on insulin sensitivity, metabolic rate and vascular health among transgender female youth at baseline and 6 months after initiation of a gondoatropin releasing hormone agonist compared to matched cisgender male controls.
Eligibility criteria
Qualifiers
Identify as a transgender female or cisgender male
Age 9-14 years at the time of enrollment
Tanner Stage 2-3 baseline pubertal development
Plan to start gonadotropin releasing hormone analogue clinically in < 2 months (for transgender females only)
Disqualifiers
Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures
Type 1 or 2 diabetes (by medical history)
On any medications that affect insulin sensitivity (e.g. metformin, antipsychotics)
Hypertension (resting BP ≥ 140/90 mm/Hg)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
30 Participants
are grouped into 2 trial groupsLocations
1University of Colorado Anschutz Medical Campus80045, AuroraColorado, United States
Sponsors and collaborators
University of Colorado, Denver
Lead sponsor
Source ClinicalTrials.gov